Your browser doesn't support javascript.
Successful use of casirivimab/imdevimab anti-spike monoclonal antibodies to enhance neutralizing antibodies in a woman on anti-CD20 treatment with refractory COVID-19.
Miyazato, Yusuke; Yamamoto, Kei; Nakaya, Yuichiro; Morioka, Shinichiro; Takeuchi, Junko S; Takamatsu, Yuki; Maeda, Kenji; Kimura, Moto; Sugiura, Wataru; Mitsuya, Hiroaki; Yano, Masao; Ohmagari, Norio.
  • Miyazato Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Yamamoto K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan. Electronic address: kyamamoto@hosp.ncgm.go.jp.
  • Nakaya Y; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Division of Infectious Diseases, Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, 411-8777, Japan.
  • Morioka S; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Takeuchi JS; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Takamatsu Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
  • Maeda K; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
  • Kimura M; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Sugiura W; Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
  • Mitsuya H; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, 162-0052, Japan.
  • Yano M; Department of Surgery, Minamimachida Hospital, Tokyo, 194-0004, Japan.
  • Ohmagari N; Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
J Infect Chemother ; 28(7): 991-994, 2022 Jul.
Article in English | MEDLINE | ID: covidwho-1828874
ABSTRACT
Management of COVID-19 patients with humoral immunodeficiency is challenging. We describe a woman with COVID-19 with multiple relapses due to anti-CD20 monoclonal antibody treatment. She was successfully treated with casirivimab/imdevimab and confirmed to have neutralizing antibodies. This case suggests that monoclonal antibodies have therapeutic and prophylactic value in patients with humoral immunodeficiency.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / COVID-19 Drug Treatment Limits: Female / Humans Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2022.03.002

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antineoplastic Agents, Immunological / COVID-19 Drug Treatment Limits: Female / Humans Language: English Journal: J Infect Chemother Journal subject: Microbiology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: J.jiac.2022.03.002